Literature DB >> 16778201

Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice.

Dmitri V Rozanov1, Alexei Y Savinov, Vladislav S Golubkov, Stephen Tomlinson, Alex Y Strongin.   

Abstract

Neoplasms have developed strategies to protect themselves against the complement-mediated host immunity. Invasion- and metastasis-promoting membrane type-1 (MT1) matrix metalloproteinase (MMP) is strongly associated with many metastatic cancer types. The relative importance of the individual functions of MT1-MMP in metastasis was, however, unknown. We have now determined that the expression of murine MT1-MMP in murine melanoma B16F1 cells strongly increased the number of metastatic loci in the lungs of syngeneic C57BL/6 mice. In contrast, MT1-MMP did not affect the number of metastatic loci in complement-deficient C57BL/6-C3-/- mice. Our results indicated, for the first time, that the anticomplement activity of MT1-MMP played a significant role in promoting metastasis in vivo and determined the relative importance of the anticomplement activity in the total metastatic effect of this multifunctional proteolytic enzyme. We believe that our results shed additional light on the functions of MT1-MMP in cancer and clearly make this protease a promising drug target in metastatic malignancies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778201     DOI: 10.1158/0008-5472.CAN-06-0539

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.

Authors:  L Liu; W Li; Z Li; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

2.  The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs.

Authors:  Rubén A Bartolomé; Sergio Ferreiro; María E Miquilena-Colina; Lorena Martínez-Prats; María L Soto-Montenegro; David García-Bernal; Juan J Vaquero; Reuven Agami; Rafael Delgado; Manuel Desco; Paloma Sánchez-Mateos; Joaquin Teixidó
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 3.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

4.  LRP1 regulates remodeling of the extracellular matrix by fibroblasts.

Authors:  Alban Gaultier; Margaret Hollister; Irene Reynolds; En-hui Hsieh; Steven L Gonias
Journal:  Matrix Biol       Date:  2009-08-20       Impact factor: 11.583

5.  Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer.

Authors:  Dmitri V Rozanov; Alexei Y Savinov; Roy Williams; Kang Liu; Vladislav S Golubkov; Stan Krajewski; Alex Y Strongin
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

6.  Non-destructive and selective imaging of the functionally active, pro-invasive membrane type-1 matrix metalloproteinase (MT1-MMP) enzyme in cancer cells.

Authors:  Albert G Remacle; Sergey A Shiryaev; Vladislav S Golubkov; John N Freskos; Michael A Brown; Amolkumar S Karwa; Arati D Naik; Carol P Howard; Carolyn J Sympson; Alex Y Strongin
Journal:  J Biol Chem       Date:  2013-06-03       Impact factor: 5.157

Review 7.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

8.  Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis.

Authors:  Albert G Remacle; Piotr Cieplak; Dong Hyun Nam; Sergey A Shiryaev; Xin Ge; Alex Y Strongin
Journal:  Oncotarget       Date:  2017-01-10

Review 9.  Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.

Authors:  Zvi Fishelson; Michael Kirschfink
Journal:  Front Immunol       Date:  2019-04-10       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.